CytoMed Therapeutics Limited is a biotechnology company dedicated to the development of innovative therapies that harness the power of the immune system to treat various diseases, including cancer
The company focuses on creating advanced cellular and gene therapies designed to enhance the body’s natural defenses against harmful cells. Through rigorous research and cutting-edge technology, CytoMed aims to bring transformative treatment options to patients, addressing unmet medical needs and improving outcomes in therapeutic areas where traditional methods may fall short. Their commitment to science and patient care positions them as a forward-thinking entity in the biopharmaceutical landscape.
SINGAPORE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQGDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic off-the-shelf immunotherapies for the treatment of various cancers, today announced that it has entered into a Business & Research Collaboration Agreement (“BRCA”) with Mumbai-based SunAct Cancer Institute Private Limited (“SunAct”), a company incorporated in the Republic of India (“India”).
SINGAPORE, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQGDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of blood and solid cancers, is pleased to announce that the first patient has been dosed in its first-in-human Phase I dose-escalation clinical trial (NCT05302037) (“ANGELICA Trial”). This trial has been registered with and has received clinical trial authorisation from the Health Sciences Authority in Singapore.
SINGAPORE, Oct. 03, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQGDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has through its subsidiary, IPSC Depository Sdn Bhd, acquired the licence and certain assets of Cellsafe International Sdn Bhd (In Liquidation), a Malaysian cord blood bank.
Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd
SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQGDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced that it has entered into a research collaboration agreement with Sengkang General Hospital Pte Ltd., a public hospital in Singapore and a member of the SingHealth Group. The two entities aim to establish a proof-of-concept for the use of an injectable cartilage regeneration therapy developed from donor-sourced umbilical cord-derived mesenchymal stem cells (UC-MSCs). This injectable therapy will undergo a proposed Phase I clinical trial, which is planned to take place in Singapore and is expected to be completed within two years.
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQGDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has obtained board approval to launch, subject to certain terms and conditions, a pilot program (“Program”) to isolate and cryo-store peripheral blood mononuclear cells (“PBMCs”) for and as a reward to loyal shareholders of CytoMed on a complimentary basis. This Program is in line with the Company’s strategy to build up a private bank of PBMC donors to develop allogeneic off-the-shelf cellular therapies using pre-qualified healthy donor blood. This Program will commence on June 1, 2024, or at such other date as CytoMed shall provide. Interested shareholders are advised to refer to CytoMed’s website for any future updates regarding the Program.
U.S. stocks traded higher this morning, with the Dow Jones gaining around 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.25% to 38,618.79 while the NASDAQ rose 0.34% to 15,661.70. The S&P 500 also rose, gaining, 0.34% to 4,971.18.
